Inhibition of CYP3A4 and CYP3A5 expression by scutellarin is not mediated via the regulation of hsa-miR-27a, 27b, 148a, 298 and 451a levels

References

• Carrillo J, Ramos S, Agundez J, et al. (1998). Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther Drug Monit 20:319–24.
   PubMed Web of Science ®Google Scholar
• Drocourt L, Ourlin JC, Pascussi JM, et al. (2002). Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 277:25125–32.
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Hustert E, et al. (2004). Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 60:231–6.
   PubMed Web of Science ®Google Scholar
• Eap CB, Fellay J, Buclin T, et al. (2004). CYP3A activity measured by the midazolam test is not related to 3435 C > T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics 14:255–60.
   PubMedGoogle Scholar
• Erin Hall, ICLAC member. 2017. Case study: the notorious Chang Liver. Available at: http://iclac.org/case-studies/chang-liver/ [accessed 28 Sep 2017].
   Google Scholar
• Flockhart DA, Rae JM. (2003). Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J 3:3–5.
   PubMed Web of Science ®Google Scholar
• Gao J, Chen G, He H, et al. (2017). Therapeutic effects of breviscapine in cardiovascular diseases: a review. Front Pharmacol 8:289.
   PubMed Web of Science ®Google Scholar
• Ghosh C, Hossain M, Solanki J, et al. (2017). Overexpression of pregnane X and glucocorticoid receptors and the regulation of cytochrome P450 in human epileptic brain endothelial cells. Epilepsia 58:576–85.
   PubMed Web of Science ®Google Scholar
• Goodwin B, Hodgson E, D'Costa DJ, et al. (2002). Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 62:359–65.
   PubMed Web of Science ®Google Scholar
• Han YL, Li D, Ren B, et al. (2012). Evaluation of impact of Herba Erigerontis injection, a Chinese herbal prescription, on rat hepatic cytochrome P450 enzymes by cocktail probe drugs. J Ethnopharmacol 139:104–9.
   PubMed Web of Science ®Google Scholar
• Hong SP, Yang JS, Han JY, et al. (2011). Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol 63:129–35.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526.
   PubMed Web of Science ®Google Scholar
• Jian TY, He JC, He GH, et al. (2012). Scutellarin Inhibits Cytochrome P450 Isoenzyme 1A2 (CYP1A2) in Rats. Phytother Res 26:1226–30.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Chang-e C, Yong L, et al. (2017). Effect and mechanism of breviscapine on CYP3A4 and CYP2C19 in Zhang's hepatic cells. Chin J Hosp Pharm 37(16):1557–62.
   Google Scholar
• Kennedy DA, Seely D. (2010). Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin Drug Saf 9:79–124.
   PubMed Web of Science ®Google Scholar
• Kovalchuk O, Filkowski J, Meservy J, et al. (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7:2152–9.
   PubMed Web of Science ®Google Scholar
• Lena E, Ilona S, Marie Louise O, et al. (2015). miRNA-27b levels are associated with CYP3A activity in vitro and in vivo. Pharmacol Res Perspect 3:e00192.
   PubMed Web of Science ®Google Scholar
• Li D, Gaedigk R, Hart SN, et al. (2012). The role of CYP3A4 mRNA transcript with shortened 3'-untranslated region in hepatocyte differentiation, liver development, and response to drug induction. Mol Pharmacol 81:86–96.
   PubMed Web of Science ®Google Scholar
• Lin Z, Guo S, Yang C, et al. (2014). In vivo effects of scutellarin on the activities of CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 by cocktail probe drugs in rats. Pharmazie 69:537–41.
   PubMed Web of Science ®Google Scholar
• Liu H, Yang X, Tang R, et al. (2005). Effect of scutellarin on nitric oxide production in early stages of neuron damage induced by hydrogen peroxide. Pharmacol Res 51:205–10.
   PubMed Web of Science ®Google Scholar
• McDonald JS, Milosevic D, Reddi HV, et al. (2011). Analysis of Circulating microRNA: preanalytical and analytical challenges. Clin Chem 57:833–40.
   PubMed Web of Science ®Google Scholar
• Pallet N, Jannot AS, El BM, et al. (2015). Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supretherapeutic tacrolimus concentrations. Am J Transplant 15:800–5.
   PubMed Web of Science ®Google Scholar
• Pan YZ, Gao W, Yu AM. (2009). MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37:2112–7.
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, et al. (2010). Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 49:239–58.
   PubMed Web of Science ®Google Scholar
• Pharmacopoeia. 2015. Pharmacopoeia of the People's Republic of China.
   Google Scholar
• Qian L, Shen M, Tang H, et al. (2012). Synthesis and protective effect of scutellarein on focal cerebral ischemia/reperfusion in rats. Molecules 17:10667–74.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu Y, Wei Z, et al. (2015). Hsa-miR-27a is involved in the regulation of CYP3A4 expression in human livers from Chinese Han population. Pharmacogenomics 16:1379–86.
   PubMed Web of Science ®Google Scholar
• Streetman DS, Bertino JS, Nafziger AN. (2000). Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187–216.
   PubMedGoogle Scholar
• Swart M, Dandara C. (2014). Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance. Front Genet 5:167
   PubMed Web of Science ®Google Scholar
• Takagi S, Nakajima M, Mohri T, Yokoi T. (2008). Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674.
   PubMed Web of Science ®Google Scholar
• Wei Y, Li L, Wang D, et al. (2014). Importin 8 regulates the transport of mature microRNAs into the cell nucleus. J Biol Chem 289:10270–5.
   PubMed Web of Science ®Google Scholar
• Wojnowski L, Kamdem LK. (2006). Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2:171.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Ai CZ, Liu Y, et al. (2012). Interactions between phytochemicals from traditional Chinese medicines and human cytochrome P450 enzymes. Curr Drug Metab 13:599–614.
   PubMed Web of Science ®Google Scholar
• Yang T, Li C, Zhang L, et al. (2013). A promising hepatocyte-like cell line, CCL-13, exhibits good liver function both in vitro and in an acute liver failure model. Transplant Proc 45:688–94.
   PubMed Web of Science ®Google Scholar
• Yang J, Luan X, Gui H, et al. (2011). Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes. Br J Pharmacol J 162:441–51.
   PubMed Web of Science ®Google Scholar
• Yap KY, See CS, Chan A. (2010). Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. Recent Pat Food Nutr Agric 2:12–55.
   PubMedGoogle Scholar
• Z L, S G, C Y, et al. (2014). In vivo effects of scutellarin on the activities of CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 by cocktail probe drugs in rats. Die Pharmazie 69:537–41.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeut 138:103–41.
   PubMed Web of Science ®Google Scholar
• Zhou X, Gao YY, Hu JY, et al. (2018). Effect of breviscapine on CYP3A metabolic activity in healthy volunteers. Eur J Clin Pharmacol 74:37–44.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang F, Li Q, et al. (2014). Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos 42:245–9.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X, et al. (2008). Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76:582–8.
   PubMed Web of Science ®Google Scholar